Clinical trials: Tirzepatide
Obstructive Sleep Apnea, Obesity
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP)…
- Trial name
- SURMOUNT-OSA (NCT05412004)
- Testing
- Tirzepatide
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 469 people
- Sponsor
- Eli Lilly and Company
Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity.
- Trial name
- SURMOUNT-J (NCT04844918)
- Testing
- Tirzepatide
- Where
- 18 sites in Japan
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
- Trial name
- SURPASS-1 (NCT03954834)
- Testing
- Tirzepatide
- Where
- 53 sites in United States, India and 3 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- SURMOUNT-2 (NCT04657003)
- Testing
- Tirzepatide
- Where
- 75 sites in United States, Argentina and 6 more
- Volunteers
- 938 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective and safe compared to dulaglutide in participants with type 2 diabetes in Japan.
- Trial name
- SURPASS J-mono (NCT03861052)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 46 sites in Japan
- Volunteers
- 636 people
- Sponsor
- Eli Lilly and Company
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss.
- Trial name
- SURMOUNT-4 (NCT04660643)
- Testing
- Tirzepatide
- Where
- 70 sites in United States, Argentina and 3 more
- Volunteers
- 783 people
- Sponsor
- Eli Lilly and Company
Healthy
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices.
- Trial name
- NCT05810597
- Testing
- Tirzepatide, Single Dose Pen, Multi-use Prefilled Pen
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.
- Trial name
- NCT03131687
- Testing
- tirzepatide, Dulaglutide
- Where
- 49 sites in United States, Poland and 2 more
- Volunteers
- 318 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-4 (NCT03730662)
- Testing
- Tirzepatide, Insulin Glargine
- Where
- 216 sites in United States, Argentina and 13 more
- Volunteers
- 2,002 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.
- Trial name
- NCT03311724
- Testing
- Tirzepatide
- Where
- 13 sites in United States
- Volunteers
- 111 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase.
- Trial name
- SURMOUNT-1 (NCT04184622)
- Testing
- Tirzepatide
- Where
- 118 sites in United States, Argentina and 8 more
- Volunteers
- 2,539 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Diabetes Mellitus, Type 2
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in…
- Trial name
- NCT05706506
- Testing
- Tirzepatide
- Where
- 32 sites in United States
- Volunteers
- 152 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin.
- Trial name
- SURPASS-5 (NCT04039503)
- Testing
- Tirzepatide
- Where
- 48 sites in United States, Czechia and 6 more
- Volunteers
- 475 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.
- Trial name
- NCT05963022
- Testing
- Tirzepatide
- Where
- 28 sites in China
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
- Trial name
- NCT04847557
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 8 more
- Volunteers
- 731 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
The main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.
- Trial name
- NCT04093752
- Testing
- Tirzepatide, Insulin Glargine
- Where
- 67 sites in Australia, China and 2 more
- Volunteers
- 917 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a…
- Trial name
- NCT03951753
- Testing
- Tirzepatide, Semaglutide
- Where
- 2 sites in Germany
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Healthy
Study of Tirzepatide in Healthy Participants
The purpose of this study is to look at how much tirzepatide gets into the bloodstream and how long the body takes to get rid of it. This study will involve a single dose of 14C radiolabelled tirzepatide.
- Trial name
- NCT04311424
- Testing
- 14C Tirzepatide
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company